UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 43

Sortiert nach

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)

Gynecologic oncology, 2018-07, Vol.150 (1), p.9-13

2018

Volltextzugriff (PDF)

Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (24), p.5554-5568

2020

Volltextzugriff (PDF)

Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance

Cancers, 2022-02, Vol.14 (4), p.958

2022

Volltextzugriff (PDF)

Comprehensive serum proteomic analysis in early endometrial cancer

Journal of proteomics, 2021-03, Vol.234, p.104099-104099, Article 104099

2021

Volltextzugriff (PDF)

SOX11 hypermethylation as a tumor biomarker in endometrial cancer

Biochimie, 2019-07, Vol.162, p.8-14

2019

Volltextzugriff (PDF)

Hypermethylation of miR-203 in endometrial carcinomas

Gynecologic oncology, 2014-05, Vol.133 (2), p.340-345

2014

Volltextzugriff (PDF)

Correction: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. Cancers 2022, 14 , 958

Cancers, 2022-05, Vol.14 (10), p.2443

2022

Volltextzugriff (PDF)

Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer

Frontiers in oncology, 2024-02, Vol.14, p.1291090-1291090

2024

Volltextzugriff (PDF)

Genomics of cervical cancer and the role of human papillomavirus pathobiology

Clinical chemistry (Baltimore, Md.), 2014-01, Vol.60 (1), p.144-146

2014

Volltextzugriff (PDF)

A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor

Gynecologic oncology reports, 2022-12, Vol.44, p.101118, Article 101118

2022

Volltextzugriff (PDF)

A prospective pilot study on the incidence of post-operative lymphedema in women with endometrial cancer

Gynecologic oncology reports, 2016-01, Vol.15 (C), p.25-28

2016

Volltextzugriff (PDF)

Enhanced Recovery After Surgery (ERAS) protocols: the impact of enhanced patient perioperative education on patient satisfaction and outcomes in gynecologic oncology practice

Gynecologic oncology, 2021-08, Vol.162, p.S149-S150

2021

Volltextzugriff (PDF)

OVARIAN GRANULOSA CELL TUMOR IN A PATIENT WITH A PATHOGENIC VARIANT IN THE CDC73 GENE (HYPERPARATHYROIDISM-JAW TUMOR SYNDROME)

AACE clinical case reports, 2019-05, Vol.5 (3), p.e222-e225

2019

Volltextzugriff (PDF)

A case series of androgen receptor (AR) inhibition by bicalutamide in combination with leuprolide acetate and exemestane in recurrent AR positive adult-type ovarian granulosa cell tumor (AGCT) (158)

Gynecologic oncology, 2022-08, Vol.166, p.S95

2022

Volltextzugriff (PDF)

Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer

Gynecologic oncology, 2018-06, Vol.149 (3), p.565-569

2018

Volltextzugriff (PDF)

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer

Clinical cancer research, 2020-09, Vol.26 (18), p.4767-4776

2020

Volltextzugriff (PDF)

Same-day discharge after robotic hysterectomy for gynecologic malignancy: a study of cost analysis and resource utilization

Gynecologic oncology, 2021-08, Vol.162, p.S270-S270

2021

Volltextzugriff (PDF)

Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers

Application of clinical genetics, 2021-01, Vol.14, p.1-9

2021

Volltextzugriff (PDF)

An open label, nonrandomized, multisite phase II trial combining bevacizumab, atezolizumab, and rucaparib for the treatment of previously treated recurrent and progressive endometrial cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5510-5510

2022

Volltextzugriff (PDF)

Abstract CT160: A Phase I, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), in patients with advanced epithelial ovarian cancer (including fallopian tube or primary peritoneal cancers) and endometrial cancers

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT160-CT160

2019

Volltextzugriff (PDF)

Syndromes of Concurrent Hypertension, Diastolic Dysfunction, and Pulmonary or Peripheral Edema in Cardio-Oncology: Case Studies, Literature Review, and New Classification System

Current treatment options in oncology, 2023-12, Vol.24 (12), p.1917-1934

2023

Volltextzugriff (PDF)

Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5508-5508

2023

Volltextzugriff (PDF)

PO13

Brachytherapy, 2023-09, Vol.22 (5), p.S71

2023

Volltextzugriff (PDF)

PO13: Bleeding in the Brachytherapy Suite - The Unwanted Surprise

Brachytherapy, 2023-09, Vol.22 (5), p.S71-S71

2023

Volltextzugriff (PDF)

Positive predictive value of liquid-based and conventional cervical Papanicolaou smears reported as malignant

Gynecologic oncology, 2003-05, Vol.89 (2), p.227-232

2003

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(40)
Berichte
(3)

Sprache

Englisch
(43)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Humans
(15)
Female
(13)
Oncology
(13)
Obstetrics & Gynecology
(9)
Aged
(6)
Middle Aged
(6)
Ovarian Cancer
(6)
Aged, 80 And Over
(5)
Ovarian Neoplasms - Pathology
(5)
Retrospective Studies
(5)
Adult
(4)
Chemotherapy
(4)
Ovarian Neoplasms - Drug Therapy
(4)
Adenocarcinoma - Pathology
(3)
Biological And Medical Sciences
(3)
Carcinoma, Squamous Cell - Pathology
(3)
Cell Line, Tumor
(3)
Cervical Cancer
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)

Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling

Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance

Comprehensive serum proteomic analysis in early endometrial cancer

SOX11 hypermethylation as a tumor biomarker in endometrial cancer

Hypermethylation of miR-203 in endometrial carcinomas

Correction: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. Cancers 2022, 14 , 958

Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer

Genomics of cervical cancer and the role of human papillomavirus pathobiology

A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor

A prospective pilot study on the incidence of post-operative lymphedema in women with endometrial cancer

Enhanced Recovery After Surgery (ERAS) protocols: the impact of enhanced patient perioperative education on patient satisfaction and outcomes in gynecologic oncology practice

OVARIAN GRANULOSA CELL TUMOR IN A PATIENT WITH A PATHOGENIC VARIANT IN THE CDC73 GENE (HYPERPARATHYROIDISM-JAW TUMOR SYNDROME)

A case series of androgen receptor (AR) inhibition by bicalutamide in combination with leuprolide acetate and exemestane in recurrent AR positive adult-type ovarian granulosa cell tumor (AGCT) (158)

Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer

Same-day discharge after robotic hysterectomy for gynecologic malignancy: a study of cost analysis and resource utilization

Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers

An open label, nonrandomized, multisite phase II trial combining bevacizumab, atezolizumab, and rucaparib for the treatment of previously treated recurrent and progressive endometrial cancer

Syndromes of Concurrent Hypertension, Diastolic Dysfunction, and Pulmonary or Peripheral Edema in Cardio-Oncology: Case Studies, Literature Review, and New Classification System

Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort

PO13

PO13: Bleeding in the Brachytherapy Suite - The Unwanted Surprise

Positive predictive value of liquid-based and conventional cervical Papanicolaou smears reported as malignant

Suchergebnisse filtern